TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05020795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Description: Clot retrieval for large vessel occlusion in acute ischaemic stroke

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular thrombectomy
Description: Clot retrieval for large vessel occlusion in acute ischaemic stroke
Study: NCT04821544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (with a focus on self-compassion; MBSC)
Description: 8-week MBSC intervention with a focus on increasing self-compassion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D at 2,000 IU/day for 8 weeks.
Study: NCT06253975

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid
Description: Use HA only as a placebo
Study: NCT05570383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).
Description: The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).
Description: The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
Study: NCT06318234

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FAPI，18F-FDG
Description: FAPI and FDG combined with PET/MR imaging in patients with rectal cancer after neoadjuvant therapy
Study: NCT06043700

Intervention type: OTHER
Intervention: No Intervention
Description: No treatment intervention will be administered.
Study: NCT03660917

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
Study: NCT05692401

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Exercise Instruction
Description: Eating and exercise patterns. Educational handouts and instructions will be provided, which are intended as a guide for subjects in intervention group. Subjects will also be given a Patient Diary to complete their daily meal intake and physical exercises. Use of and return of the diary is optional but encouraged. It has been found that use of a patient diary to record food intake keeps one from eating more than they planned and can be a useful tool in weight control.
Study: NCT05989048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: The participants will receive single active dose sufficient to treat 1 migraine headache of moderate or severe intensity within Treatment Phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of matching placebo taken within Treatment Phase.
Study: NCT06041893

Intervention type: DRUG
Intervention: ATG-LDPTCy
Description: antithymocyte globulin with low dose post-transplant cyclophosphamide
Study: NCT04738487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab
Description: Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg. Participants receive the coformulation by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
Study: NCT05171543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periapical surgery with placement of an allograft and a membrane
Description: Periapical surgery will be done followed by placement of an allograft into the defect and a membrane over the defect before closure of the flap.
Study: NCT04902131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL
Description: Single dose cross-over bioequivalence trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A MENOPUR powder including solvent for solution for injection, 75 IU
Description: Single dose cross-over bioequivalence trial
Study: NCT06242600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drainage of the bladder by indwelling Foley catheter
Description: Drainage of the bladder by transurethral catheterization with an indwelling Foley catheter of patients undergoing a TUR-B procedure and in need of a Foley catheter for up to 24 hrs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Drainage of the bladder by indwelling Foley catheter
Description: Drainage of the bladder by transurethral catheterization with an indwelling Foley catheter of patients undergoing a TUR-B procedure and in need of a Foley catheter for up to 24 hrs.
Study: NCT06402643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pterygium Excision
Description: Pterygium will be surgically removed utilizing conventional resection techniques, entailing a blunt resection of the head, neck, and body of the pterygium. Subsequent to the resection, the surgical site will be polished using a surgical diamond burr if deemed necessary, and hemostasis will be achieved using bipolar cautery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pterygium Excision
Description: Pterygium will be surgically removed utilizing conventional resection techniques, entailing a blunt resection of the head, neck, and body of the pterygium. Subsequent to the resection, the surgical site will be polished using a surgical diamond burr if deemed necessary, and hemostasis will be achieved using bipolar cautery.
Study: NCT04733495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05051540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sigvaris Compreflex Inelastic Compression Wrap
Description: Compreflex compression system using wraps to apply compression of 30-40 mmHg.
Study: NCT05931484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemfibrozil
Description: Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of Placebo
Study: NCT05222269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PTF
Description: 68Ga-PTF will be injected intravenously at three time points during the course of the standard treatment of the patient.
Study: NCT04807517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: All participants in the study will receive open-label treatment with orally administered buspirone for the full duration of the 16-week trial. Buspirone has high affinity for serotonin 5-HT1A and 5-HT2 receptors and moderate affinity for dopamine D2 receptors. It is approved for the management of generalized anxiety disorder in adults.
Study: NCT04733495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Undergo personalized resistance exercises
Study: NCT05568407

Intervention type: DRUG
Intervention: Avelumab
Description: As used in real world practice
Study: NCT06630962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Navigation Program
Description: A salaried financial navigator will be hired by the study sites. All responsibilities of the navigator will revolve around the structured financial navigation program. There is currently no research indicating that such a role has been incorporated at cancer centers in sub-Saharan Africa.~Through this program, the financial navigator will educate participants on financial literacy, insurance plans and payment options available through charities and financial assistance programs. In addition to providing financial counseling, the financial navigator will verify participant insurance documents, maintain records of financial agreements, and coordinate payments with insurance companies.
Study: NCT06629376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Candida Utilis Uricase for Injection
Description: According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Candida Utilis Uricase for Injection
Description: According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
Study: NCT06176040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVO101
Description: TAVO101 IV Infusion.
Study: NCT06629376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Candida Utilis Uricase for Injection
Description: According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Candida Utilis Uricase for Injection
Description: According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Candida Utilis Uricase for Injection
Description: According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Recombinant Candida Utilis Uricase for Injection
Description: According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
Study: NCT05538754

Intervention type: DEVICE
Group type: OTHER
Intervention: EVO ICL
Description: The EVO ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
Study: NCT05926271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: See arm description earlier.
Study: NCT05926960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: encorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: binimetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipilimumab
Description: ipilimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab
Description: nivolumab
Study: NCT05030311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 25 mg (b.i.d)
Description: LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 25 mg (b.i.d) as a tablet.
Description: LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet in open label phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LOU064 25 mg (b.i.d) as a tablet.
Description: LOU064 25 mg was administered by oral route twice a day (b.i.d) as a tablet in open label phase.
Study: NCT06176040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVO101
Description: TAVO101 IV Infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVO101
Description: TAVO101 IV Infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVO101
Description: TAVO101 IV Infusion.
Study: NCT06153693

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily (QD) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorundrostat Dose 1
Description: 50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorundrostat Dose 2
Description: 50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
Study: NCT05187013

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mHealth for Hypertension in Homeless Persons
Description: SMS text messages sent to participants' mobile phones

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth for Hypertension in Homeless Persons
Description: SMS text messages sent to participants' mobile phones
Study: NCT06121843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986393
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986393
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986393
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alnuctamab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Specified dose on specified days
Study: NCT05192057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline inhalation
Description: Hypertonic Saline inhalation is thought to increase mucociliary clearance of the airways
Study: NCT05786066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 6 MG
Description: Perampanel will be administered 2.5 hours before Ketamine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered 2.5 hours before Ketamine infusion
Study: NCT05568459

Intervention type: OTHER
Intervention: Non-Interventional
Description: No study treatment will be administered in this study.
Study: NCT05192096

Intervention type: BEHAVIORAL
Intervention: Train-the-trainer workshop
Description: To deliver health-related information to trainees, which facilitate improving their knowledge, confidence, and ability to share and discuss health-related information with others, including service users, families and friends.
Study: NCT02832531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg)
Description: Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG.
Study: NCT06321029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Tune-Up Group
Description: The eDTU and iDTU interventions will consist of 6 weekly group sessions lasting 90 minutes per session offered over a 6-8 week period. Each series will be co-facilitated by one diabetes care and education specialist and one behavioral health interventionist. Enrollment in each series will consist of 4-10 patients per group. The intervention components integrate key strategies that have been demonstrated to be effective in previous studies: motivational interviewing and introduction to stages of change; diabetes education; cognitive behavioral therapy with a particular emphasis on identification of cognitive distortions, thought stopping and cognitive reframing; emotional regulation; social support and miscarried helping; and behavioral strategies to support diabetes self-management. Each session will involve a psychoeducational portion, group discussion, and take-home assignments to be completed between sessions.
Study: NCT05548361

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: active chlorhexidine and placebo probiotic
Description: the randomized patients will be receive active chlorhexidine rinse and placebo probiotic

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: placebo chlorhexidine and active probiotic
Description: the randomized patients will receive placebo chlorhexidine rinse and active probiotic

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: active chlorhexidine and active probiotic
Description: the randomized patients will receive active chlorhexidine rinse and active probiotic
Study: NCT05750160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Music therapy that have been made by Music Therapist after Focus Group discussion, given three times a week for 4 weeks
Study: NCT05639114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: ianalumab s.c. monthly or quarterly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: ianalumab s.c. monthly or quarterly
Study: NCT06569979

Intervention type: OTHER
Intervention: Survey
Description: The survey was developed using the Google Forms platform. The first part of the questionnaire consisted of descriptive information such as age, gender, duration of academic experience. In addition to this informations, the questionnaire also included information related the status of use ICF in any fields.~In the other part of the questionnaire, a total of 59 questions (16 related to body functions, 3 related to body structures, 30 related to activity and participation, 10 related to environmental factors) were asked to the academicians whether these categories are present in the amputee rehabilitation course content. Academicians were asked to answer yes or no to each question.
Study: NCT06569888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIPUS stimulation
Description: Low Intensity Pulsed Ultrasound stimulation of the gut at the pre-clinically optimized conditions and energy dosage
Study: NCT06570564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The arm crank ergometer
Description: Before starting the program, patients will perform an adaptation session for familiarization with the ergometer and also to identify the training load. For this, patients will perform 10 bouts of two minutes of exercising with a minimum load and two minute passive intervals between bouts. Patients will be instructed to maintain 50 revolutions per minute (RPM) during the exercise. Subsequently, to determine the training load for each session, patients will perform a progressive test where the load will be increased by 10 watts every minute of the test, following the protocol of two minutes of exercise with two minutes of interval

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bicycle ergometer
Description: bicycle ergometer program will consist of a bicycling exercise 3 days per week. Exercise intensity was set at 70% of maximal load with 30 minutes per session. The exercise protocol also incorporated warm-up and cool-down sessions that involved stretches of the major lower limb muscle groups (total exercise time, 40-60 minutes)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: Supervised treadmill exercise as routine physiotherapy program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: Supervised treadmill exercise as routine physiotherapy program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: Supervised treadmill exercise as routine physiotherapy program
Study: NCT06571240

Intervention type: PROCEDURE
Intervention: Anterior cruciate ligament reconstruction
Description: Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
Study: NCT06258512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with a narrative approach.
Description: Health social workers will carry out a intervention with a narrative approach, through its training profile based on transversal skills, which will consist of 10 sessions carried out over five months. The interval between sessions will be of two weeks with a specific duration of fifty minutes per session. This type of intervention, with the objective of reorienting and redefining the demand or the initial problems that motivated the consultation, gives space to the patient\&#39;s subjective complaint, as well as to locate the understanding of the discomfort and the symbolic meaning of the symptoms.~That is, recognizing the physical symptoms while listening to stories of chaos to legitimize both the user and his symptoms, an encounter that allows return the user to its context without feeling rejected or judged by the health system.
Study: NCT05639114

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo s.c. monthly
Study: NCT06570382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videos: Taste messaging focused
Description: Participants in this intervention will watch the taste focused videos.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videos: Health messaging focused
Description: Participants in this intervention will watch the health focused videos.